328
Participants
Start Date
June 30, 2012
Primary Completion Date
January 31, 2013
Study Completion Date
April 30, 2013
Sofosbuvir
Sofosbuvir 400 mg tablet administered orally once daily
RBV
Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
PEG
Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
Weill Cornell Medical College, New York
Mount Sinai School of Medicine, New York
Binghamton Gastroenterology Associates, Binghamton
Hospital of the University of Pennsylvania, Philadelphia
Whitman Walker Clinic, Washington D.C.
Capital Medical Associates, Washington D.C.
Johns Hopkins University, Lutherville
Metropolitan Research, Fairfax
Inova Fairfax Hospital Center for Liver Diseases, Falls Church
Bon Secours St. Mary's Hospital of Richmond, Inc., Richmond
Digestive and Liver Disease Specialists, Norfolk
Digestive Health Specialists, PA, Winston-Salem
Duke University Medical Center, Durham
Asheville Gastroenterology Associates, P.A., Asheville
Infectious Disease Specialist of Atlanta, Decatur
Gastrointestinal Specialists of Georgia, PC, Marietta
Digestive Healthcare of Georgia, Atlanta
Borland-Groover Clinic Baptist, Jacksonville
Internal Medicine Specialists, Orlando
University of Miami Center for Liver Diseases, Miami
South Florida Center of Gastroenterology, P.A., Wellington
Advanced Research Institute, New Port Richey
Nashville Gastrointestinal Specialists, Inc, Nashville
Gastro One, Germantown
Graves-Gilbert Clinic, Bowling Green
Indianapolis Gastroenterology Research Foundation, Indianapolis
Henry Ford Health System, Novi
Minnesota Gastroenterology, P.A., Saint Paul
Kansas City Gastroenterology and Hepatology, Kansas City
Gastroenterology Associates, LLC, Baton Rouge
Southwest Infectious Disease Clinical Research, Inc., Dallas
Research Specialists of Texas, Houston
Alamo Medical Research, San Antonio
University of Colorado, Aurora
South Denver Gastroenterology, PC, Englewood
Southwest C.A.R.E. Center, Santa Fe
Kaiser Permanente, Los Angeles
Peter J. Ruane, MD, Inc., Los Angeles
Anthony Mills MD, Inc., Los Angeles
University of California San Diego, San Diego
SCTI Research Foundation, Coronado
Medical Associates Research Group, Inc., San Diego
Kaiser Permanente, San Diego
Quest Clinical Research, San Francisco
Virginia Mason Medical Center, Seattle
University of Alabama Birmingham, Birmingham
University of Florida, Gainesville
Orlando Immunology Center (ACH), Orlando
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
The Research Institute, Springfield
Comprehensive Clinical Research, Berlin
ID Care, Hillsborough
University Gastroenterology, Providence
The Miriam Hospital, Providence
Fundacion De Investigacion De Diego, San Juan
Lead Sponsor
Gilead Sciences
INDUSTRY